Table 3

Number of cases/controls and ORsa of cancer according to predicted mEH activity and GSTM3 genotype

Oral/pharyngeal cancer patientsbLaryngeal cancer patientsc
Predicted mEH activityPredicted mEH activity
LowIntermediateHighLowIntermediateHigh
GSTM3 AA 1 (Reference)2.4 (1.2–4.8)1.6 (0.7–4.1)1 (Reference)2.0 (1.0–4.1)1.1 (0.4–3.1)
Cases/controls30/6240/4115/1728/6235/4112/17
GSTM3 AB or BB1.1 (0.4–2.8)0.9 (0.4–2.3)4.2 (1.0–16.9)2.0 (0.8–5.5)2.2 (1.0–5.2)13.1 (3.5–48.4)
Cases/controls18/1012/218/513/1822/2113/5
  • a Data on smoking and/or alcohol drinking were missing for eight control individuals, six oral/pharyngeal cancer cases, and six laryngeal cancer cases; ORs adjusted for sex-, age-, smoking-, and alcohol-related variables.

  • b Interaction test between predicted mEH activity and GSTM3 genotype (likelihood ratio test, 2 df): P = 0.08.

  • c Interaction test between predicted mEH activity and GSTM3 genotype (likelihood ratio test, 2 df): P = 0.03.